SOS enzymes of the pancreas.
Fedez
launches it
from his Instagram profile with a series of stories in which he denounces the lack of it throughout northern Italy and announces that he will write to Aifa.
''I'm receiving lots of reports about Milan and Bologna.
It's a problem that I've also encountered - says Fedez -, having been operated on and almost all of my pancreas was removed, I need enzymes to eat and assimilate food.
There is only one company in Italy that produces pancreatic enzymes and it seems that enzymes have not been found in pharmacies for a month now.
I had a small supply of them but they haven't been available for a month now and now I can't find them anymore.
How can it be solved?
Friends who produce pancreatic enzymes, produce them, otherwise we can't eat or we eat but then when we go to the bathroom it's not fun.
Help us enzyme friends''.
And then in other stories he adds: ''It really seems that the drug in northern Italy no longer exists, send us the reports to the Fedez Foundation.
We will contact Aifa''.
And he adds: ''The situation is quite serious as if there was a lack of specific medicines for heart patients and they cannot be found''.
The Ministry of Health, "situation paid close attention":
"This is a known situation independent of the regulatory activities of Aifa, which has already provided patients and healthcare workers with adequate information, including operational information, for some time".
Thus in a note the Ministry of Health in relation to the shortage of drugs to treat pancreatic diseases reported, among others, by Fedez.
"To date, the only manufacturing company (Viatris Italia Srl) has communicated the impossibility of satisfying demand due to excess demand", adds the ministry.
"However, as already communicated by AIFA through the procedures ordinarily used in the event of drug shortages,
the Agency allows healthcare facilities to import similar drugs authorized abroad
, in the event that the facilities themselves encounter discontinuities in the supply, at the level of the distribution networks to which they have access. Furthermore, pharmacies that cannot find the product in the usual distribution channels can place a direct order with the owner via the specific Customer Service service".
The ministry assures that it is following the issue "with great attention and implements all relevant activities aimed at guaranteeing the therapeutic continuity of patients".
The manufacturing company, "committed to mitigating problems":
"We are in daily contact with the manufacturing company to mitigate supply difficulties and reduce the impact on patients."
The manufacturer "has assured us that it is taking all necessary measures to make Creon available, so as to minimize the impact on patients".
This is how he responded to ANSA Viatris, the company that holds the marketing authorization and distributor of Creon in Italy.
The shortage
of this drug, necessary for patients with pancreatic insufficiency,
has continued with varying severity for months
and was also reported this morning by Fedez on Instagram.
Viatris specified that it has "received indications from the drug manufacturer, Abbott, of some difficulties in the supply of Creon (pancrelipase). The supply difficulties are due to the high demand at a global level. These difficulties are not linked to supply problems quality, safety or efficacy relating to the production of Creon".
The company confirms to ANSA, as already announced by the Italian Medicines Agency in a note last October, that
"difficulties in supply could extend until 31/12/2025"
committing to "communicate any changes in a timely manner ".:
Reproduction reserved © Copyright ANSA